CTTNBP2 and neoplasm: In summary, the CTTNBP2 CRE SNV1 variant leads to reduced expression of CTTNBP2 which appears to enhance the tumorigenic phenotype in HEK-293 cells, indicating a potential role for CTTNBP2 as a novel tumor suppressor.